One of the unique things that sets GeoInvesting’s service apart from other research firms isn’t just the institutional quality of our research – but the fact that we provide it to our members as we work to undertake it. This […]
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then its […]
Director Joseph Manko of Horton Capital Management was an insider that we came to know as a recurring Form 4 filer for Repro-Med. His filings helped shape the way we viewed Repro Med Systems (OOTC:REPR) as an investment, especially through the […]
Bluelinx Holdings Inc. (NYSE:BXC) is a leading distributor of building and industrial products in the US. We started tracking the company in late 2016 as an asset sale put them ahead of schedule in their restructuring efforts. We disclosed our long position […]
Over the last ten years we have worked hard to earn the trust of investors with our stock research service. “Find the truth, report the truth, invest in the truth” has been the motto that defines our culture at GeoInvesting. […]
We don’t like to toot our horn when we are right here at Geo, but sometimes we get it right. If you had been a member and allocated $1,000 when we pointed out ZYNEX INC (OTCQB:ZYXI) in June as a […]
In July of 2016, several media outlets, as well as a top activist publication, contacted us. They wanted to know more about the role we were taking to prevent American Securities (“PE Firm”), a private equity firm from “stealing” public […]
By Maj Soueidan, co-founder GeoInvesting You probably noticed that I often use the term “Information Arbitrage” (InfoArb) to highlight free or easy money opportunities hidden in corners of the microcap universe that investors can overlook. An information arbitrage exists when […]